Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03758924 · ClinicalTrials.gov registry record · Phase 2
Study of ANAVEX2-73 in Patients With Rett Syndrome
A Phase 2 study, sponsored by Anavex Life Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT03758924: Completed Phase 2 study, sponsored by Anavex Life Sciences.
NCT03758924 is a Phase 2 study that has completed, run by Anavex Life Sciences. The registered enrollment target is 31 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03758924, a Phase 2 study, has completed, sponsored by Anavex Life Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
Phase 2 safety, tolerability and efficacy study is designed as a double-blind, randomized, placebo-controlled study. 7-week placebo-controlled study of ANAVEX2-73 oral solution for the treatment of patients with RTT 18 years or older. A voluntary option will be offered for all patients who meet the exposure criteria for ANAVEX2-73 to continue a 12-week open label extension.
Primary Outcome
Incidence of Adverse Events
Interventions
- DRUG Placebo
- DRUG ANAVEX2-73
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2019-02-28 |
| Est. Completion | 2020-10-30 |
| Phase | Phase 2 |
What the finished NCT03758924 record still lists
NCT03758924 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03758924 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03758924 about?
NCT03758924 is a clinical study titled "Study of ANAVEX2-73 in Patients With Rett Syndrome". Phase 2 safety, tolerability and efficacy study is designed as a double-blind, randomized, placebo-controlled study. 7-week placebo-controlled study of ANAVEX2-73 oral solution for the treatment of patients with RTT 18 years or older. A voluntary option will be offered for all patients who meet the...
What is the current status of trial NCT03758924?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2019-02-28. Estimated completion is 2020-10-30.
What interventions are being tested in trial NCT03758924?
The interventions under investigation include: Placebo (DRUG), ANAVEX2-73 (DRUG).
Who is sponsoring clinical trial NCT03758924?
This trial is sponsored by Anavex Life Sciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03758924's enrollment target sits among peer trials
31 1578th of 2000 higher than 419 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI